Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BV, chidamide, mitoxantrone liposome, or golidocitinib in relapsed/refractory CD30+ CTCL
ChiCTR2600124536Phase 4Not yet recruiting
- Sponsor
- Huashan Hospital
- Start
- May 2026
- Modality
- Small Molecules, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of brentuximab vedotin, tucidinostat, mitoxantrone-liposome and golidocitinib in cutaneous T-cell lymphoma (CTCL), mycosis fungoides (MF) and Sézary syndrome (SS), sponsored by Huashan Hospital. Primary endpoint: Objective response rate after four treatment cycles. Planned start May 2026; status: not yet recruiting.
02
Drugs
brentuximab vedotintucidinostatmitoxantrone-liposomegolidocitinib
03
Conditions
cutaneous T-cell lymphoma (CTCL)mycosis fungoides (MF)Sézary syndrome (SS)
Beyond the preview
Go deeper on ChiCTR2600124536.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600124536.